776: James Short of Celadon Pharmaceuticals discusses their business strategy and operational progress

The Vox Markets Podcast

Innhold levert av jruss88 and Vox Markets Podcast. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av jruss88 and Vox Markets Podcast eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

2y ago 14:00

MP3•Episoder hjem

James Short, CEO of Celadon Pharmaceuticals #CEL, a UK-based pharmaceutical company focused on the development and supply of natural, cannabis-based medicines, provides an update on its business strategy and operations.

Highlights

§ Successfully completed sixth harvest from its Phase 1 grow facility, with initial results from the selected test batches showing high quality, consistent growing of pharmaceutical grade, high THC medical cannabis

§ Nearing completion of all preparatory work ahead of GMP inspection by MHRA, having undertaken extensive internal audits and independent third-party testing

§ High level of new patient enquiries to LVL clinic for participation in the chronic pain study, with feedback from initial patients reporting improvements in quality of life

§ Phase 2 grow facility build on track and expected to become operational in Q1 2023, following which the Company will aim to expand its high THC medical cannabis grow capacity to three tonnes per year

To read the full RNS click here

1913 episoder

#Trading #Business #Vox Markets #Need To Know